心房利钠肽受体拮抗剂可改善糖尿病大鼠的肾小球高滤过。

Antagonist for atrial natriuretic peptide receptors ameliorates glomerular hyperfiltration in diabetic rats.

作者信息

Kikkawa R, Haneda M, Sakamoto K, Koya D, Shikano T, Nakanishi S, Matsuda Y, Shigeta Y

机构信息

Third Department of Medicine, Shiga University of Medical Science, Japan.

出版信息

Biochem Biophys Res Commun. 1993 Jun 15;193(2):700-5. doi: 10.1006/bbrc.1993.1681.

DOI:10.1006/bbrc.1993.1681

PMID:8390251

Abstract

To evaluate the possible contribution of atrial natriuretic peptide (ANP) to the development of glomerular hyperfiltration, we examined the effect of non-peptide competitive antagonist for biological receptors of ANP, HS-142-1, on glomerular filtration rate (GFR) and renal plasma flow (RPF) in diabetic rats. Increased GFR and RPF in diabetic rats were significantly ameliorated by the injection of HS-142-1, while blood pressure remained unchanged. Urinary cyclic GMP excretion was significantly higher in diabetic rats than in control rats and HS-142-1 decreased urinary cGMP excretion significantly. These results indicate that atrial natriuretic peptide contributes to the development of glomerular hyperfiltration and hyperperfusion in diabetes and HS-142-1 might be useful in the treatment of them.

摘要

为评估心房利钠肽（ANP）在肾小球高滤过发生发展过程中可能的作用，我们研究了ANP生物受体的非肽类竞争性拮抗剂HS-142-1对糖尿病大鼠肾小球滤过率（GFR）和肾血浆流量（RPF）的影响。注射HS-142-1可显著改善糖尿病大鼠升高的GFR和RPF，而血压保持不变。糖尿病大鼠尿中环鸟苷酸（cGMP）排泄显著高于对照大鼠，HS-142-1可显著降低尿cGMP排泄。这些结果表明，心房利钠肽在糖尿病时肾小球高滤过和高灌注的发生发展中起作用，HS-142-1可能对其治疗有用。